Epalex gets backing for migraine, epilepsy treatments

Epalex, a member of the 2017 Biopharma Pitch Summit cohort, recently closed a $10 million Series A round. The funding will enable the UC Davis spinout to further develop novel therapies for migraine and epilepsy.

Learn more about Epalex